Assertio narrows 2025 guidance to $110M-$112M as Rolvedon pull-forward shapes cash flow outlook
Source: SeekingAlpha
2025-11-10 18:22:17 ET
More on Assertio Holdings
- Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript
- Assertio stock rises after revenue beat
- Seeking Alpha’s Quant Rating on Assertio Holdings
- Historical earnings data for Assertio Holdings
- Financial information for Assertio Holdings
Read the full article on Seeking Alpha
For further details see:
Assertio narrows 2025 guidance to $110M–$112M as Rolvedon pull-forward shapes cash flow outlook
Assertio Therapeutics Inc.
NASDAQ: ASRT
ASRT Trading
-1.6% G/L:
$11.67 Last:
15,090 Volume:
$11.59 Open:
ASRT Latest News
March 03, 2026 04:30:00 pm
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
January 12, 2026 04:15:00 pm
Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements
January 09, 2026 01:45:00 pm
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial
ASRT Stock Data
$74,884,126
6,160,134
17.12%
23
N/A
Pharmaceuticals
Healthcare
US
Lake Forest
